Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: A phase II study of the hellenic cooperative oncology group

Gynecologic Oncology

Volumn 85, Issue 3, 2002, Pages 476-482

  Dimopoulos, Meletios A ^a   Papadimitriou, Christos A ^a   Sarris, Kyrillos ^a   Aravantinos, Gerassimos ^b   Kalofonos, Charalambos ^c   Gika, Dimitra ^a   Gourgoulis, Georgios M ^a   Efstathiou, Eleni ^a   Skarlos, Dimosthenis ^d   Bafaloukos, Dimitrios ^e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b AGII ANARGIRI CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

^d H Dunant Hospital   (Greece)

^e Metropolitan Hospital   (Greece)

Author keywords

Cervical cancer; Cisplatin; Ifosfamide; Paclitaxel

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA; VOMITING;

EID: 0036080739     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2002.6649     Document Type: Article

References (27)

1. Carcinoma of the uterine cervix: Current status and future directions
2. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix
3. Chemotherapy in advanced and recurrent cervical cancer
4. The role of chemotherapy in squamous cell carcinoma of the uterine cervix: A review
5. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study
6. Paclitaxel has moderate activity in squamous cervix cancer: A Gynecologic Oncology Group study
7. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix
8. Reporting results of cancer treatment
9. The calculation of received dose intensity
10. The description of chemotherapy delivery options and pitfalls
11. Optimal two-stage designs for phase II clinical trials
12. Nonparametric estimation from incomplete observations
13. Micro-computer-assisted univariate survival data analysis using Kaplan-Meier life table estimators
14. Chemotherapy for cervical carcinoma: Factors determining response and implications for clinical trial design
15. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer
16. Bleomycin, ifosfamide, cisplatinum in pelvic recurrence of previously irradiated cervical carcinoma: A second look
17. Cisplatin and Ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix
18. Randomized phase III trial of bleomycin, vindesine, mitomycin-C and cisplatin (BEMP) versus cisplatin in disseminated squamous-cell carcinoma of the uterine cervix
19. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
20. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix
21. Paclitaxel, ifosfamide and cisplatin chemotherapy for recurrent or persistent squamous-cell cervical cancer
22. Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin
23. Factors predicting response to chemotherapy and survival in patients with metastatic or recurrent squamous cell cervical carcinoma: A multivariate analysis
24. Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
25. Phase II study of ifosfamide and mesna in onsquamous carcinoma of the cervix: A Gynecologic Oncology Group study
26. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group study
27. Paclitaxel delivered as a 3-hour infusion with cisplatin in patients with gynecologic cancers: Unexpected incidence of neurotoxicity